The Survival Advantage of “Supratotal” Resection of Glioblastoma Using Selective Cortical Mapping and the Subpial Technique

Central Nervous System Cancers

(2017) Steven S. Brem et al.   Journal of the National Comprehensive Cancer Network

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Current trends in the management of glioblastoma in a French University Hospital and associated direct costs

(2016) A. M. Henaine et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection?

(2016) Yan Michael Li et al.   JOURNAL OF NEUROSURGERY

Individualized Map of White Matter Pathways

(2016) Birkan Tunç et al.   NEUROSURGERY

Molecular Predictors of Long-Term Survival in Glioblastoma Multiforme Patients

(2016) Jie Lu et al.   PLoS One

Has the survival of patients with glioblastoma changed over the years?

(2015) R M deSouza et al.   BRITISH JOURNAL OF CANCER

Treatment by specialist surgical neurooncologists improves survival times for patients with malignant glioma

(2015) Ursalan A. Khan et al.   JOURNAL OF NEUROSURGERY

Detection of human brain tumor infiltration with quantitative stimulated Raman scattering microscopy

(2015) Minbiao Ji et al.   Science Translational Medicine

When Gross Total Resection of a Glioblastoma Is Possible, How Much Resection Should Be Achieved?

(2014) Kaisorn L. Chaichana et al.   World Neurosurgery

Is Supratotal Resection of Glioblastoma in Noneloquent Areas Possible?

(2014) Hugues Duffau   World Neurosurgery

IDH1/IDH2but NotTP53Mutations Predict Prognosis in Bulgarian Glioblastoma Patients

(2014) Gergana Stancheva et al.   Biomed Research International

5-aminolevulinic acid (5-ALA) fluorescence guided surgery of high-grade gliomas in eloquent areas assisted by functional mapping. Our experience and review of the literature

(2013) Alessandro Della Puppa et al.   ACTA NEUROCHIRURGICA

A survival analysis of GBM patients in the West of Scotland pre- and post-introduction of the Stupp regime

(2013) Mario Teo et al.   BRITISH JOURNAL OF NEUROSURGERY

Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers

(2013) Steven Brem et al.   CANCER

The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience

(2013) A. Gutenberg et al.   JOURNAL OF NEURO-ONCOLOGY

A new philosophy in surgery for diffuse low-grade glioma (DLGG): Oncological and functional outcomes

(2013) H. Duffau   NEUROCHIRURGIE

Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma

(2012) Pasquale De Bonis et al.   ACTA NEUROCHIRURGICA

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

(2012) Surasak Phuphanich et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The Definition of Primary and Secondary Glioblastoma

(2012) H. Ohgaki et al.   CLINICAL CANCER RESEARCH

Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: Efficacy and toxicity

(2012) Petra Miglierini et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

(2012) Roger Stupp et al.   EUROPEAN JOURNAL OF CANCER

Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival

(2012) Daniel Orringer et al.   JOURNAL OF NEUROSURGERY

Gross Total Resection Rates in Contemporary Glioblastoma Surgery

(2012) Philippe Schucht et al.   NEUROSURGERY

The Risk of Getting Worse: Surgically Acquired Deficits, Perioperative Complications, and Functional Outcomes After Primary Resection of Glioblastoma

(2012) Sasha Gulati et al.   World Neurosurgery

The Necessity of Preserving Brain Functions in Glioma Surgery: The Crucial Role of Intraoperative Awake Mapping

(2012) Hugues Duffau   World Neurosurgery

Vaccines for glioblastoma and high-grade glioma

(2011) Christopher J Wheeler et al.   Expert Review of Vaccines

Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin

(2011) Albert Lai et al.   JOURNAL OF CLINICAL ONCOLOGY

An extent of resection threshold for newly diagnosed glioblastomas

(2011) Nader Sanai et al.   JOURNAL OF NEUROSURGERY

Awake surgery for WHO Grade II gliomas within “noneloquent” areas in the left dominant hemisphere: toward a “supratotal” resection

(2011) Yordanka N. Yordanova et al.   JOURNAL OF NEUROSURGERY

A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma

(2011) Ashwatha Narayana et al.   JOURNAL OF NEUROSURGERY

Early-Stage Progress on Glioma Vaccines

(2011) V. Brower   JNCI-Journal of the National Cancer Institute

Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial

(2011) Christian Senft et al.   LANCET ONCOLOGY

Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review

(2011) Pieter L Kubben et al.   LANCET ONCOLOGY

Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance

(2011) D. Kuhnt et al.   NEURO-ONCOLOGY

Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States

(2010) S. A. Grossman et al.   CLINICAL CANCER RESEARCH

Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities

(2010) J. Pallud et al.   NEUROLOGY

Surgical management of World Health Organization Grade II gliomas in eloquent areas: the necessity of preserving a margin around functional structures

(2010) Santiago Gil-Robles et al.   Neurosurgical Focus

First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience

(2010) Hans Christoph Bock et al.   NEUROSURGICAL REVIEW

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

ASSOCIATION OF SURGICALLY ACQUIRED MOTOR AND LANGUAGE DEFICITS ON OVERALL SURVIVAL AFTER RESECTION OF GLIOBLASTOMA MULTIFORME

(2009) Matthew J. McGirt et al.   NEUROSURGERY

Operative techniques for gliomas and the value of extent of resection

(2009) Nader Sanai et al.   Neurotherapeutics

Role of Convective Flow in Carmustine Delivery to a Brain Tumor

(2009) Davis Yohanes Arifin et al.   PHARMACEUTICAL RESEARCH

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme

(2008) Matthew J. McGirt et al.   JOURNAL OF NEUROSURGERY

Independent association of extent of resection with survival in patients with malignant brain astrocytoma

(2008) Matthew J. McGirt et al.   JOURNAL OF NEUROSURGERY

GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME

(2008) Nader Sanai et al.   NEUROSURGERY

Functional Outcome after Language Mapping for Glioma Resection

(2008) Nader Sanai et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE